Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | GAPDH | P04406 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | STAT6 | P42226 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14243961 | 1.00 | MEN1 (0.63) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL19502714 | 1.00 | MEN1 (0.63) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL667836 | 1.00 | MEN1 (0.63) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL3150637 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL20579764 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL29435131 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL1996593 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL18486352 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL157531 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL29390532 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739343-A2 | CIRCULAR RNA VACCINES FOR SEASONAL FLU AND METHODS OF USES | Shanghai Circode Biomed Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| WO-2025011529-A2 | CIRCULAR RNA VACCINES FOR SEASONAL FLU AND METHODS OF USES | Shanghai Circode Biomed Co., Ltd. (CN) | 2025-01-16 | — | — | WO | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2026098357-A1 | FREEZE-DRIED NUCLEIC ACID-LOADED LIPID NANOPARTICLE AND RECONSTITUTION METHOD THEREOF | KUDO BIOTECHNOLOGY, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102302-A1 | POLYNUCLEOTIDES CONTAINING A MODIFIED 3'-REGION | MODERNATX, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739343-A2 | CIRCULAR RNA VACCINES FOR SEASONAL FLU AND METHODS OF USES | Shanghai Circode Biomed Co., Ltd (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4737571-A1 | VARICELLA ZOSTER VIRUS (VZV) VACCINE | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736871-A1 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109976-A1 | SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS | RNAV8 BIO INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3983545-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | Vertex Pharmaceuticals Incorporated (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022066757-A1 | IMPROVED METHODS AND COMPOSITIONS FOR EXPRESSION OF NUCLEIC ACIDS IN CELLS | MYELOID THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-107690480-B | Evaluation of CAS9 molecule/guide RNA molecule complexes | 爱迪塔斯医药公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114206463-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114206827-A | Lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3966327-A1 | CRISPR/CAS ALL-IN-TWO VECTOR SYSTEMS FOR TREATMENT OF DMD | Vertex Pharmaceuticals Incorporated (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022032154-A2 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109976-A1 | SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS | UPF1, RNGTT, NSUN3 | MEN1 3173/4885KMT2A 1199/4885ADORA3 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.